Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Anal Cancer Pipeline Review, H2 2016 - Market Constitutes Approx 13 Molecules - Research and Markets

Research and Markets
Posted on: 19 Sep 16

Research and Markets has announced the addition of the "Anal Cancer - Pipeline Review, H2 2016" drug pipelines to their offering.

Anal Cancer pipeline therapeutics constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by Companies and remaining by the Universities/Institutes.

This report provides comprehensive information on the therapeutic development for Anal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anal Cancer and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Anal Cancer Overview
  3. Therapeutics Development
  4. Pipeline Products for Anal Cancer - Overview
  5. Pipeline Products for Anal Cancer - Comparative Analysis
  6. Anal Cancer - Therapeutics under Development by Companies
  7. Anal Cancer - Therapeutics under Investigation by Universities/Institutes
  8. Anal Cancer Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Anal Cancer - Products under Development by Companies
  13. Anal Cancer - Products under Investigation by Universities/Institutes
  14. Anal Cancer - Companies Involved in Therapeutics Development
  • Advaxis, Inc.
  • Amgen Inc.
  • Cell Medica Limited
  • Eli Lilly and Company
  • Genticel S.A.
  • ISA Pharmaceuticals B.V.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Oryx GmbH & Co. KG
  • PDS Biotechnology Corporation
  • Sun Pharma Advanced Research Company Ltd.
  • Taiwan Liposome Company, Ltd.

For more information about this drug pipelines report visit

Related Topics: Oncology Drugs

View source version on

Business Wire

Last updated on: 19/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.